Novel therapy in Parkinson's disease: Adenosine A2A receptor antagonists

Nikoletta Szabó, Zsigmond Tamás Kincses, László Vécsei

Research output: Contribution to journalReview article

23 Citations (Scopus)


Introduction: Parkinson's disease (PD) is a progressive neurodegenerative disorder. To date, most of the currently available therapies in PD target the dopaminergic system and none of these therapeutic approaches have been proven to modify the course of the disease. To various extents, these drugs can also cause motor and non-motor complications. A novel target, the adenosine A2A receptor (AA2AR), was recently identified, blockade of which may alleviate Parkinsonian symptoms, reduce motor fluctuations and potentially afford neuroprotection. Areas covered: This review is based on a PubMed search covering the relationship of the adenosine receptors and PD. The role of the AA2AR is reviewed and the results of preclinical investigations of antagonists are assessed. A synopsis of current drug development is provided, with a special focus on the pharmacokinetics and relevant clinical trials. Expert opinion: The localization of the AA2AR in the central nervous system, the ultra structural localization and the molecular mechanism of its action reveal the potential importance of the AA2AR in movement disorders. The theoretical background and experimental data indicate that AA2AR antagonists may have a potential therapeutic effect in Parkinson's disease. More importantly, the putative neuroprotective effect needs further investigation.

Original languageEnglish
Pages (from-to)441-455
Number of pages15
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number4
Publication statusPublished - Apr 1 2011



  • Parkinson-disease
  • adenosine A receptor
  • istradefylline
  • preladenant
  • vipadenant

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this